Department of Oncology, University of Turin, Turin, Italy
Tiziana Crepaldi
Department of Oncology, University of Turin, Turin, Italy
Patrizia Gasparini
Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Michela Casanova
Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Andrea Ferrari
Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Gabriella Sozzi
Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Roberto Chiarle
CeRMS, Center for Experimental Research and Medical Studies, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, United States
Carola Ponzetto
Department of Oncology, University of Turin, Turin, Italy; CeRMS, Center for Experimental Research and Medical Studies, Turin, Italy
Embryonal Rhabdomyosarcoma (ERMS) and Undifferentiated Pleomorphic Sarcoma (UPS) are distinct sarcoma subtypes. Here we investigate the relevance of the satellite cell (SC) niche in sarcoma development by using Hepatocyte Growth Factor (HGF) to perturb the niche microenvironment. In a Pax7 wild type background, HGF stimulation mainly causes ERMS that originate from satellite cells following a process of multistep progression. Conversely, in a Pax7 null genotype ERMS incidence drops, while UPS becomes the most frequent subtype. Murine EfRMS display genetic heterogeneity similar to their human counterpart. Altogether, our data demonstrate that selective perturbation of the SC niche results in distinct sarcoma subtypes in a Pax7 lineage-dependent manner, and define a critical role for the Met axis in sarcoma initiation. Finally, our results provide a rationale for the use of combination therapy, tailored on specific amplifications and activated signaling pathways, to minimize resistance emerging from sarcomas heterogeneity.